United StatesÚltimas notícias

Takeda Pharmaceutical Company (NYSE:TAK) has announced positive topline results from its two pivotal Phase 3 trials evaluating zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.

US stocks slid after delayed shutdown-era jobs data showed rising unemployment, while bitcoin climbed in a fresh sign of its growing divergence from traditional markets.

Ripple is celebrating the rapid ascent of its RLUSD stablecoin into the top tier of regulated USD tokens, underscoring strong institutional adoption, regulatory alignment and growing global integration.

Former Alameda Research chief executive Caroline Ellison has been transferred from federal prison to a reentry facility ahead of an early release, highlighting her cooperation in the FTX case and renewed public attention on the exchange’s collapse.

VYNE Therapeutics (NASDAQ:VYNE) and Yarrow Bioscience have entered into a definitive all-stock merger agreement, with the combined company expected to operate under the name Yarrow Bioscience and trade on Nasdaq under the ticker YARW.

ABM Industries (NYSE:ABM) reported a fiscal fourth-quarter net income of $34.8 million, or 56 cents per share, recovering from a loss in the same period last year.

However, the company’s adjusted earnings, which exclude restructuring costs and expenses related to mergers and acquisitions, were 88 cents per share, missing Wall Street expectations.

General Mills (NYSE:GIS) reported its second-quarter results for the fiscal year 2025, showing a 7 percent decrease in net sales to $4.9 billion

Processa Pharmaceuticals (NASDAQ:PCSA) provided a Phase 2 clinical update for its combination therapy, NGC-Cap (PCS6422 + capecitabine), on December 17, 2025.

Vistagen (NASDAQ:VTGN) announced disappointing results from its PALISADE-3 Phase 3 clinical trial of intranasal fasedienol, a treatment for social anxiety disorder.

The study failed to meet its primary endpoint, which was based on the change from baseline in the Subjective Units of Distress Scale (SUDS).

SCHMID Group (NASDAQ:SHMD) reported its unaudited H1 2025 financial results, revealing a significant decline in revenue to €16.9 million, compared to €29.7 million in the same period a year earlier.

Toro Co. (NYSE:TTC) reported a profit of $73 million for its fiscal fourth quarter, or 74 cents per share, beating Wall Street expectations.

Traws Pharma (NASDAQ:TRAW) reported promising interim results from its Phase 2 trial of ratutrelvir, a ritonavir-free Mpro inhibitor, in the treatment of COVID-19.

The oral treatment, administered at a 600 mg once-daily dose for 10 days, was compared against PAXLOVID™ in a randomized, open-label study involving 37 patients—25 receiving ratutrelvir and 12 receiving PAXLOVID™.